Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
October 1, 2026 · 2:30 AM · NEW YORK
Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. The findings were shared today in an oral presentation at the 35th European Academy of Dermatology and Venereology (EADV) Annual Congress in Vienna, Austria. Tilrekimig is an investigational, potential first-in-class trispecific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation through concurrent high-affinity binding to interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP). By directly blocking TSLP together with its downstream effectors, tilrekimig is designed to provide broader cytokine pathway coverage and potentially more durable clinical responses. Tilrekimig is also designed to have an extended half-life of about 37 days, which is anticipated to support monthly administration.
- PublishedOctober 1, 2026 · 2:30 AM
- LocationNEW YORK
- IndustryHealth
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →
